Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?
Adaptimmune shares jumped 52% on October 8, 2025, amid heavy speculative trading, but remain down about 75% year-over-year and trade near $0.20. The company sold its main T-cell therapy programs to US WorldMeds for $55 million upfront, cleared its debt, and now faces “substantial doubt” about its ability to continue. Analysts rate the stock as high risk, with no major firm recommending a Buy.